Brenig Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$65M
- Investors
-
6
Brenig Therapeutics General Information
Description
Operator of a drug development company intended to utilize an AI/ML approach through clinical candidates across multiple therapeutic areas. The company is redefining the frontier of aging science with a resolute focus on addressing neurodegeneration and translating groundbreaking research into transformative therapies, enabling drug discovery companies to defeat neurodegenerative diseases.
Contact Information
Website
www.brenigther.comCorporate Office
- 100 Chestnut Street
- Suite 300
- Somerville, MA 02143
- United States
Corporate Office
- 100 Chestnut Street
- Suite 300
- Somerville, MA 02143
- United States
Brenig Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 23-Jul-2024 | $65M | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC | 22-Apr-2021 | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Brenig Therapeutics Patents
Brenig Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025235687-A1 | Lrrk2 inhibitors | Pending | 08-May-2024 | ||
| AU-2023249498-A1 | Lrrk2 inhibitors | Active | 04-Apr-2022 | ||
| AU-2023249498-B2 | Lrrk2 inhibitors | Active | 04-Apr-2022 | ||
| EP-4504722-A2 | Lrrk2 inhibitors | Pending | 04-Apr-2022 | ||
| EP-4504722-A4 | Lrrk2 inhibitors | Pending | 04-Apr-2022 | A61K31/501 |
Brenig Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bayshore Global Management | Family Office | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Torrey Pines Investment | Venture Capital | Minority | ||
| BioGeneration Ventures | Venture Capital | Minority | ||
| i2020 Accelerator | Accelerator/Incubator | Minority |
Brenig Therapeutics FAQs
-
When was Brenig Therapeutics founded?
Brenig Therapeutics was founded in 2021.
-
Where is Brenig Therapeutics headquartered?
Brenig Therapeutics is headquartered in Somerville, MA.
-
What industry is Brenig Therapeutics in?
Brenig Therapeutics’s primary industry is Drug Discovery.
-
Is Brenig Therapeutics a private or public company?
Brenig Therapeutics is a Private company.
-
What is Brenig Therapeutics’s current revenue?
The current revenue for Brenig Therapeutics is .
-
How much funding has Brenig Therapeutics raised over time?
Brenig Therapeutics has raised $73M.
-
Who are Brenig Therapeutics’s investors?
Bayshore Global Management, New Enterprise Associates, Torrey Pines Investment, BioGeneration Ventures, and i2020 Accelerator are 5 of 6 investors who have invested in Brenig Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process